Get started
RECURSION PHARMACEUTICALS, INCRECURSION PHARMACEUTICALS, INCRECURSION PHARMACEUTICALS, INC

RECURSION PHARMACEUTICALS, INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast

RXRX trade ideas

$42 TARGET $RXRX BUY NOW!The triple bottom chart pattern usually emerges after an extended downtrend with bears dominating the market. While the first bottom might reflect regular price fluctuations, the second bottom signals that the bulls are gathering strength and gearing up for a potential reversal. The third bottom demonstrates robust support, suggesting that bears may surrender when the price surpasses resistance levels. ALSO: Investing in Recursion Pharmaceuticals (RXRX) offers intriguing possibilities for several reasons: Innovative Technology: NASDAQ:RXRX utilizes artificial intelligence (AI) and machine learning to expedite drug discovery. Their BioHive-2 supercomputer, powered by Nvidia AI chips, is among the most powerful accelerated computing systems globally. Partnerships: NASDAQ:RXRX has formed alliances with major tech and healthcare leaders, including Nvidia ( NASDAQ:NVDA ), which invested $50 million into its operations. These collaborations aim to streamline drug discovery, making it faster and more cost-effective. Promising Pipeline: NASDAQ:RXRX boasts a strong lineup of drug candidates, and their technology has already shown promising results. Their merger with Exscientia, another biotech company focused on AI-driven drug discovery, has created a more robust, vertically integrated platform. Potential for High Returns: While investing in NASDAQ:RXRX involves risks, it also holds the potential for significant returns. The company's innovative approach could transform the healthcare industry, making it a potential "10-bagger" (a stock that increases tenfold in value). Long-term Vision: RXRX seeks to shorten the drug discovery process from years to months and significantly reduce costs. This long-term vision could lead to substantial growth if successful.
NASDAQ:RXRXLong
by sej4974
2
DON'T WALK, RUN!!RXRX is at the heart of AI ADVANCEMENT in biotech. Pioneers in bringing new drugs to market faster and cheaper. One of the largest biological and chemical datasets built for drug discovery and development. Meet BIOHIVE - the world's largest pharmaceutical supercomputer. Entry (starter position) 8.28 - 9.55 Add on breakout above 9.55 Target: $16-$23 in the coming months. overshoot: $28-$35 if momentum kicks in hard... clean chart. all lined up. very nice looking setup. Not financial advice.
NASDAQ:RXRX
by originalrick001
2
RXRX Jan 7th 2025GT + FIB + previous high. Fibonacci Retracement Bounce: The price is bouncing near the 0.5 Fibonacci retracement level, which is a common support zone in an uptrend. This suggests buyers are stepping in at this level. Risk-to-Reward Ratio: The trade setup shows a favorable risk-to-reward ratio (~4:1), with the potential upside significantly larger than the downside. Bullish Structure: The price has been making higher highs and higher lows, indicating a clear uptrend on the 4-hour chart. Consolidation Near Support: The price appears to be consolidating near a strong support zone (~$7.40), which could act as a launching point for further upward movement. Breakout Potential: If the price clears the resistance near $7.80–$8.00, there’s a potential move toward $9.00 and above (a 22% upside as indicated on the chart).
NASDAQ:RXRXLong
by tringuyentpt
RXRX long in next couple monthsThis was a request and I want to journal what I got with the dowsing work I do. I expect this could pop in the short term, but it will likely keep going down. There may be some support around $4.84, but this is based on the number I get as a percent down, which is 22%. The thing with these numbers though sometimes is that it could also be points, like 2.20 points. But, I'm sticking with the percent for this. The other thing is that I do get advice as a date, which is October, ugh & I now recognize it's the 22nd. So, that's the number 22 again. So I try again and get 29th, but I would also keep a heads up for September 29th just in case. I did get the option of an "extreme value buy". So, something could be brewing in the future.
NASDAQ:RXRXLong
by JenRz
Prescription for Gains!Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49. In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value. With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target. NASDAQ:RXRX
NASDAQ:RXRXLong
by The_Trading_Mechanic
3
RXRX - BIOTECH SQUEEZE PLAY RXRX - Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Consolidating since April, look left and see the explosive moves. Grab cheap long dated calls and wait for news to come out. Easy R/R. Calls swing 100% on small moves and I've got a good bit cheaply Jan 2025 calls. 9 & 10 dollar strikes. Huge opportunity here to cash in on any news or favorable Earnings Report in a few days. Short squeeze targets 10-12 dollars, manage your own risk. Will be dumping calls on impulsive move. $6 looks to be a strong bottom here, under that for any time other than a flash sale, this trade is invalid, and I won't be holding any calls. NOT INVESTMENT ADVICE. TRADE YOUR PLAN!
NASDAQ:RXRXLong
by mortimerkylej
Thanksgiving Gifts for ALL - RXRX - BIOTECH SQUEEZE PLAYRecursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. Chart looks primed, bounced off 6 dollar range a few times and is peaking out of the downtrend. I fully expect to find support along that trendline and chop until news sends this thing flying. Short squeeze potential here and fibs look like a big move could be in store before Thanksgiving which will line up with news around Earnings time. Holding long dated calls and some shares. Calls dated Jan 2025 or later. 8,9,10 strikes Fibs for targets. LFG!
NASDAQ:RXRXLong
by mortimerkylej
Recursion Pharmaceuticals, Inc. (RXRX)High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR-Cas9 Editing CRISPR-Cas9 editing is a scalable technology for mapping of biological pathways, but it has been reported to cause a variety of undesired large-scale structural changes to the genome. We performed an arrayed CRISPR-Cas9 scan of the genome in primary human cells, targeting 17,065 genes for knockout with 101,029 guides. High-dimensional phenomics reveals a “proximity bias” in which CRISPR knockouts bear unexpected phenotypic similarity to knockouts of biologically-unrelated genes on the same chromosome arm, recapitulating both canonical genome structure and structural variants. Transcriptomics connects proximity bias to chromosome-arm truncations. Analysis of published large-scale knockout and knockdown experiments confirms that this effect is general across cell types, labs, Cas9 delivery mechanisms, and assay modalities, and suggests proximity bias is caused by DNA double-strand-breaks with cell cycle control in a mediating role. Finally, we demonstrate a simple correction for large-scale CRISPR screens to mitigate this pervasive bias while preserving biological relationships.
NASDAQ:RXRXLong
by mgiuliani
1
Biotechnology runnersBiotechnology companies develop therapeutics or processes that advance medicine, pharmaceuticals, genomics, food production, and the production of biofuels. Biotech stocks are risky investments, because the development stage of the asset pipeline can take a long time and usually does not even workout in the end. A good example of a long-term successful biotech company is MRNA. But the list of long-term losers is much longer. Here's a top 11 list of Biotechnology runners the past month. 1hr ext chart with the tickerTracker Oscillator set to length 13RSI color coded with it's respective ticker. Can 1 out of 11 of these biotechnology companies become a long-term winner in the future? IMGN NERV NNOX VYNE LFCR CTIC APYX MRSN ICVX QTRX RXRX
NASDAQ:RXRXLong
by Options360